ADAR1 Capital Management »

Spero Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Spero Therapeutics (SPRO) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Spero Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Spero Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Spero Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.6M 1.1M 1.47

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Spero Therapeutics

Vanguard Group
ADAR1 Capital Management
Atlas Venture Life Science Advisors
Alphabet
AWM Investment Company
Millennium Management
DAFNA Capital Management
Squarepoint Ops
Citadel Advisors
DLK Investment Management
Charles Schwab Investment Management
Mackenzie Financial
Two Sigma Securities
Dimensional Fund Advisors
Russell Investments

View all funds holding Spero Therapeutics